You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAclidinium
Accession NumberDB08897
TypeSmall Molecule
GroupsApproved
DescriptionAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Structure
Thumb
Synonyms
Aclidinium
External Identifiers
  • LAS-34273
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tudorza GenuairPowder, metered400 mcgRespiratory (inhalation)Astrazeneca Canada Inc2013-09-13Not applicableCanada
Tudorza PressairInhalant400 ug/1Respiratory (inhalation)Astra Zeneca Pharmaceuticals Lp2015-07-01Not applicableUs
Tudorza PressairInhalant400 ug/1Respiratory (inhalation)Forest Laboratories, Inc.2012-07-23Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Bretaris GenuairNot Available
Eklira Genuair Not Available
Brand mixtures
NameLabellerIngredients
Duaklir GenuairAstrazeneca Canada Inc
Salts
Name/CASStructureProperties
Aclidinium Bromide
320345-99-1
Thumb
  • InChI Key: XLAKJQPTOJHYDR-QTQXQZBYSA-M
  • Monoisotopic Mass: 563.07996248
  • Average Mass: 564.555
DBSALT000003
Categories
UNIIK17VY42F6C
CAS number727649-81-2
WeightAverage: 484.651
Monoisotopic: 484.161624833
Chemical FormulaC26H30NO4S2
InChI KeyASMXXROZKSBQIH-VITNCHFBSA-N
InChI
InChI=1S/C26H30NO4S2/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2/q+1/t20?,22-,27?/m0/s1
IUPAC Name
(3R)-3-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azabicyclo[2.2.2]octan-1-ium
SMILES
OC(C(=O)O[[email protected]]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
Pharmacology
IndicationAclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Structured Indications
PharmacodynamicsAclidinium does not prolong the QTc interval or have significant effects on cardiac rhythm.
Mechanism of actionAclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinyes
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinyes
antagonist
HumanP08912 details
Related Articles
AbsorptionBioavailability, healthy subjects = 6%; T max, healthy subjects = 10 minutes; Time to steady state, healthy subjects = 2 days;
Volume of distribution

Following IV administration, the volume of distribution is 300 L

Protein bindingNot Available
Metabolism

The major route of metabolism of aclidinium bromide is hydrolysis, which occurs both chemically and enzymatically by esterases in the plasma. Aclidinium bromide is rapidly and extensively hydrolyzed to its alcohol and dithienylglycolic acid derivatives, neither of which binds to muscarinic receptors and are pharmacologically inactive.

Route of eliminationIntravenously administered radiolabelled aclidinium bromide was administered to healthy volunteers and was extensively metabolized with 1% excreted as unchanged aclidinium. Approximately 54% to 65% of the radioactivity was excreted in urine and 20% to 33% of the dose was excreted in feces. The combined results indicated that almost the entire aclidinium bromide dose was eliminated by hydrolysis. After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose.
Half lifePlasma half-life = 2.4 minutes (indicating that aclidinium is very rapidly hydrolyzed in plasma into its two inactive metabolites and has a low chance of causing systemic side effects). Effective half-life = 5-8 hours.
Clearance

Total clearance, IV dose, young healthy subjects = 170 L/h (inter-individual variability of 36%)

ToxicityMost common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideAclidinium may increase the anticholinergic activities of Anisotropine Methylbromide.Approved
Atracurium besylateAclidinium may increase the anticholinergic activities of Atracurium besylate.Approved
AtropineAclidinium may increase the anticholinergic activities of Atropine.Approved, Vet Approved
BenactyzineAclidinium may increase the anticholinergic activities of Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Aclidinium.Approved
BenzatropineAclidinium may increase the anticholinergic activities of Benzatropine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenAclidinium may increase the anticholinergic activities of Biperiden.Approved
Botulinum Toxin Type AAclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BAclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
ChlorphenoxamineAclidinium may increase the anticholinergic activities of Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Aclidinium.Approved
CimetropiumAclidinium may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopentolateAclidinium may increase the anticholinergic activities of Cyclopentolate.Approved
DarifenacinAclidinium may increase the anticholinergic activities of Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Demecarium.Approved
DesloratadineAclidinium may increase the anticholinergic activities of Desloratadine.Approved, Investigational
DexetimideAclidinium may increase the anticholinergic activities of Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineAclidinium may increase the anticholinergic activities of Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Aclidinium is combined with DPDPE.Investigational
DronabinolAclidinium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Edrophonium.Approved
EluxadolineAclidinium may increase the constipating activities of Eluxadoline.Approved
EthopropazineAclidinium may increase the anticholinergic activities of Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Aclidinium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineAclidinium may increase the anticholinergic activities of Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideAclidinium may increase the anticholinergic activities of Gallamine Triethiodide.Approved
Ginkgo bilobaThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.Approved
GlycopyrroniumAclidinium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Aclidinium is combined with Heroin.Approved, Illicit
HexamethoniumAclidinium may increase the anticholinergic activities of Hexamethonium.Experimental
HomatropineAclidinium may increase the anticholinergic activities of Homatropine.Approved
Huperzine AThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Aclidinium.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydromorphone.Approved, Illicit
HyoscyamineAclidinium may increase the anticholinergic activities of Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.Approved
Ipratropium bromideAclidinium may increase the anticholinergic activities of Ipratropium bromide.Approved
IsoflurophateThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Aclidinium.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Lofentanil.Illicit
LoxapineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Loxapine.Approved
MalathionThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineAclidinium may increase the anticholinergic activities of Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineAclidinium may increase the anticholinergic activities of Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Aclidinium.Approved
MetixeneAclidinium may increase the anticholinergic activities of Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.Approved
MianserinMianserin may increase the anticholinergic activities of Aclidinium.Approved
MinaprineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideAclidinium may increase the anticholinergic activities of N-butylscopolammonium bromide.Vet Approved
NabiloneAclidinium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Normethadone.Approved, Illicit
NVA237Aclidinium may increase the anticholinergic activities of NVA237.Investigational
OpiumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Opium.Approved, Illicit
OrphenadrineAclidinium may increase the anticholinergic activities of Orphenadrine.Approved
OxybutyninAclidinium may increase the anticholinergic activities of Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Aclidinium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumAclidinium may increase the anticholinergic activities of Oxyphenonium.Approved
PancuroniumAclidinium may increase the anticholinergic activities of Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pentazocine.Approved, Vet Approved
PentoliniumAclidinium may increase the anticholinergic activities of Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Aclidinium is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Physostigmine.Approved
PipecuroniumAclidinium may increase the anticholinergic activities of Pipecuronium.Approved
PirenzepineAclidinium may increase the anticholinergic activities of Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Aclidinium is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Aclidinium.Approved
Potassium ChlorideAclidinium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Aclidinium.Approved, Investigational
ProcyclidineAclidinium may increase the anticholinergic activities of Procyclidine.Approved
PropanthelineAclidinium may increase the anticholinergic activities of Propantheline.Approved
PropiverineAclidinium may increase the anticholinergic activities of Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Aclidinium.Approved
QuinidineAclidinium may increase the anticholinergic activities of Quinidine.Approved
RamosetronAclidinium may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineAclidinium may increase the anticholinergic activities of Scopolamine.Approved
Scopolamine butylbromideAclidinium may increase the anticholinergic activities of Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.Approved, Investigational
SolifenacinAclidinium may increase the anticholinergic activities of Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Aclidinium.Approved
TacrineThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tapentadol.Approved
TiotropiumAclidinium may increase the anticholinergic activities of Tiotropium.Approved
TolterodineAclidinium may increase the anticholinergic activities of Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Aclidinium is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.Approved, Vet Approved
TrihexyphenidylAclidinium may increase the anticholinergic activities of Trihexyphenidyl.Approved
TrimethaphanAclidinium may increase the anticholinergic activities of Trimethaphan.Approved
TropicamideAclidinium may increase the anticholinergic activities of Tropicamide.Approved
TrospiumAclidinium may increase the anticholinergic activities of Trospium.Approved
TubocurarineAclidinium may increase the anticholinergic activities of Tubocurarine.Approved
UmeclidiniumAclidinium may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumAclidinium may increase the anticholinergic activities of Vecuronium.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160 ]
  2. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013 ]
  3. Jones P: Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. [PubMed:23553509 ]
External Links
ATC CodesR03AL05R03BB05
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (1.25 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.8883
Caco-2 permeable-0.6509
P-glycoprotein substrateSubstrate0.7017
P-glycoprotein inhibitor INon-inhibitor0.8103
P-glycoprotein inhibitor IINon-inhibitor0.6449
Renal organic cation transporterInhibitor0.6092
CYP450 2C9 substrateNon-substrate0.7784
CYP450 2D6 substrateNon-substrate0.809
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8536
CYP450 2C9 inhibitorNon-inhibitor0.8817
CYP450 2D6 inhibitorNon-inhibitor0.5813
CYP450 2C19 inhibitorNon-inhibitor0.8022
CYP450 3A4 inhibitorNon-inhibitor0.7154
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.808
Ames testNon AMES toxic0.7753
CarcinogenicityNon-carcinogens0.9292
BiodegradationReady biodegradable0.6794
Rat acute toxicity2.6182 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7765
hERG inhibition (predictor II)Non-inhibitor0.6484
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Powder, meteredRespiratory (inhalation)
Powder, meteredRespiratory (inhalation)400 mcg
InhalantRespiratory (inhalation)400 ug/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5840279 No1996-06-212016-06-21Us
US6071498 No1996-06-212016-06-21Us
US6681768 No2002-08-072022-08-07Us
US6750226 No2000-09-052020-09-05Us
US7078412 No2000-07-162020-07-16Us
US8051851 No2007-04-222027-04-22Us
US9056100 No2000-07-072020-07-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00152 mg/mLALOGPS
logP3.07ALOGPS
logP0.45ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)10.35ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.76 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity141.33 m3·mol-1ChemAxon
Polarizability52.09 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinuclidines. These are compounds containing a 1-azabicyclo[2.2.2]octane moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinuclidines
Sub ClassNot Available
Direct ParentQuinuclidines
Alternative Parents
Substituents
  • Quinuclidine
  • Phenol ether
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Tertiary alcohol
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Cazzola M, Page CP, Matera MG: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. [PubMed:23566013 ]
Comments
comments powered by Disqus
Drug created on June 04, 2013 17:58 / Updated on December 08, 2016 02:40